Thyroid Cancer

A Case-Based Approach
Softcover Nachdruck of the original 1. Auflage 2016
ISBN: 978-3-319-35835-2
Verlag: Springer International Publishing

Buch, Englisch, 430 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 674 g

Comprised exclusively of clinical cases covering the diagnosis and treatment of thyroid cancer and related clinical issues, this concise, practical casebook will provide clinicians in endocrinology and oncology with the best real-world strategies to properly manage the various forms of thyroid cancer that they may encounter. Each chapter is a case report, written by recognized experts, that opens with a unique clinical presentation, followed by a description of the diagnosis, assessment and therapy, as well as the case outcome, literature review,  clinical pearls and pitfalls, and bibliography.  All recommendations are based on evidence-based clinical practice guidelines and recent literature. Cases included illustrate treatment for both low and high risk differentiated thyroid cancer, including surgical approaches, radioiodine therapy, and novel chemotherapies and targeted therapies, as well as postoperative follow-up and special issues. Additional cases demonstrate the management of medullary thyroid cancer, thyroid lymphoma and anaplastic thyroid cancer. Pragmatic and reader-friendly, Thyroid Cancer: A Case-Based Approach will be an excellent resource for clinical endocrinologists and oncologists, endocrine fellows, residents and students alike.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Durante, Cosimo

Cooper, David S.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Endokrinologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

Part 1 Low Risk Differentiated Thyroid Cancer: Preoperative diagnosis.- Chapter 1 A patient with a single thyroid nodule suspicious for follicular neoplasm according to the Bethesda System for Reporting Thyroid Cytopathology: molecular evaluation.- Part 2 Low Risk Differentiated Thyroid Cancer: Initial management: extent of surgery and use of radioactive iodine therapy.- Chapter 2 A case of a small (1 to 2 cm) papillary thyroid cancer in a young patient:  lobectomy vs. total thyroidectomy.- Chapter 3 The decision-making process for prophylactic central neck dissection in a patient presenting with nodular thyroid disease suspicious for malignancy on cytology assessment: role of preoperative ultrasound and molecular marker testing.- Chapter 4 Incidentally discovered micropapillary thyroid cancer.- Chapter 5 Completion thyroidectomy in a patient with low risk papillary cancer.- Chapter 6 A case of multifocal micropapillary thyroid cancer.- Chapter 7 A papillary thyroid cancer with minimal extra-thyroidal extension.- Chapter 8 A case of a papillary thyroid cancer with lymph node metastases found on prophylactic central neck dissection (subclinical disease, micrometastases).- Chapter 9 Papillary thyroid cancer with central neck lymph node metastases.- Chapter 10 A patient with a large minimally invasive follicular thyroid cancer.-  Chapter 11 A young patient with intrathyroidal papillary thyroid cancer and family history of differentiated thyroid cancer.- Chapter 12 A child with papillary thyroid cancer and locally advanced disease but no distant metastasis.- Part 3 Low Risk Differentiated Thyroid Cancer: Postoperative follow-up.- Chapter 13 A patient with papillary thyroid cancer and biochemical evidence of disease at the 1-yr follow-up visit.- Chapter 14 Low but detectable suppressed thyroglobulin levels in thyroid cancer patients’ follow-up: How to interpret and manage these cases?.- Chapter 15 A young patient with papillary thyroidcancer and biochemical evidence of disease at the follow-up visits and increasing serum Tg values at the follow up assessments.- Chapter 16 A young patient with recurrent lymph node involvement:  imaging, cytology, Tg washout.- Part 4 Low Risk Differentiated Thyroid Cancer: Special issues.- Chapter 17 Papillary thyroid carcinoma diagnosed during pregnancy.- Chapter 18 Risks of Thyroid Hormone Suppression for Differentiated Thyroid Cancer in the Elderly.- Chapter 19 A patient in whom one pathologist says she has cancer and another says that the lesion is benign.- Chapter 20: A case with postsurgical hypoparathyroidism.- Chapter 21 A case with postsurgical recurrent laryngeal nerve damage and nerve monitoring.- Part 5 High Risk Differentiated Thyroid Cancer: The need for additional therapy.- Chapter 22 A case of papillary thyroid cancer without aggressive histological features with nodal metastases detected during follow-up in a younger patient.- Chapter 23 A case of papillary thyroid cancer without aggressive histological features with nodal metastases in an older patient.- Chapter 24 A patient with a large Hurthle cell carcinoma of the thyroid and nodal metastases.- Chapter 25 A case of a large, invasive PTC with gross residual disease (pT4) after surgery.- Part 6 High Risk Differentiated Thyroid Cancer: The use of radioiodine.- Chapter 26 A patient with papillary carcinoma of the thyroid with elevated serum thyroglobulin but negative imaging studies.- Chapter 27 A young child with papillary thyroid cancer and metastatic pulmonary disease:  whole issue of radioactive iodine therapy in children.- Chapter 28 A patient with bone metastases from follicular carcinoma of the thyroid.- Chapter 29 Radioiodine Therapy in Lactating Women with High Risk Differentiated Thyroid Cancer.- Part 7 High Risk Differentiated Thyroid Cancer: The use of local treatments and novel systemic chemotherapies.- Chapter 30 A case of a patient with radioactiveiodine refractory differentiated thyroid cancer with progressive neck disease (latero-cervical lymph nodes) and stable, small lung metastases.- Chapter 31 A case of an elderly patient with advanced disease and non radioiodine avid metastases.- Chapter 32 Radioactive iodine refractory differentiated thyroid cancer with multiple organ progressive disease.- Chapter 33 Radioactive iodine refractory differentiated thyroid cancer and lung lesions causing bleeding.- Chapter 34 A patient with follicular thyroid cancer and a painful bone metastasis at risk for pathologic fracture.- Chapter 35 Differentiated thyroid cancer and brain.- Part 8 High Risk Differentiated Thyroid Cancer: Novel chemotherapy and toxicity.- Chapter 36 Radioactive iodine refractory, advanced differentiated thyroid cancer receiving tyrosine kinase inhibitor treatment: checking for drug-drug interactions.- Chapter 37 A patient with advanced differentiated radioactive iodine-refractory thyroid cancer receiving tyrosine kinase inhibitor treatment: managing hypertension, QTc prolongation, dermatologic and gastrointestinal adverse events.- Part 9 Medullary Thyroid Cancer: Postoperative management.- Chapter 38 Management of post-operative hypercalcitoninemia in medullary thyroid cancer.- Chapter 39 A patient with metastatic medullary thyroid carcinoma (MTC) and tumor-related diarrhea.- Chapter 40 Clinical management of a patient with a locally recurrent medullary thyroid cancer and asymptomatic slowly progressing distant metastases.- Chapter 41 A patient with an advanced medullary thyroid cancer and progressive, symptomatic distant metastases: when to start systemic therapy.- Chapter 42 Medical Treatment Decision-Making for Advanced, Progressive Medullary Thyroid Cancer.- Part 10 Medullary Thyroid Cancer: Special issues.- Chapter 43 Screening leading to diagnosis of C cell hyperplasia.- Chapter 44 Increased basal calcitonin in nodular goiter: Is it micromedullary thyroid cancer?.- Chapter 45 Timing and extent of surgery for a pediatric patient with hereditary MTC and positive screening for the S891A RET mutation.- Part 11 Thyroid lymphoma.- Chapter 46 Thyroid Lymphoma: Differential Diagnosis.- Part 12 Anaplastic thyroid cancer.- Chapter 47 Anaplastic Thyroid Cancer: Surgery or Not in Locally Advanced Disease.

Über Autor(innen)

David S. Cooper, MD, Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Cosimo Durante, MD, Department of Internal Medicine, University of Rome - Sapienza, Rome, Italy